GlassScriptPhysician profile
Nirmala Murugavel
NPI 1558363887
$920.15
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $14.14 · 2021: $12.98 · 2022: $18.63 · 2023: $208 · 2024: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $146.43 | 2024 | Watchman Flx |
| Amgen INC. | $139.14 | 2020-2024 | Krystexxa |
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Lexicon Pharmaceuticals, INC. | $122.80 | 2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $110.54 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $39.65 | 2019 | |
| Eisai INC. | $36.52 | 2019 | |
| Pfizer INC. | $32.14 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $31.92 | 2019 | |
| Sanofi Pasteur INC. | $29.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.06 | 2019 | |
| Novo Nordisk INC | $18.63 | 2022 | |
| Lilly USA, LLC | $17.17 | 2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $14.42 | 2019 | |
| Dexcom, INC. | $12.98 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $12.83 | 2019 | |
| Allergan, INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmala Murugavel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.